| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10916268 | Nuclear Medicine and Biology | 2005 | 5 Pages |
Abstract
The goal of targeted radionuclide therapy is the deposition in malignant cells of sterilizing doses of radiation without damaging normal tissue. The radiopharmaceutical [131I]meta-iodobenzylguanidine ([131I]MIBG) is an effective single agent for the treatment of neuroblastoma. However, uptake of the drug in malignant sites is insufficient to cure disease. A growing body of experimental evidence indicates exciting possibilities for the integration of gene transfer with [131I]MIBG-targeted radiotherapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Robert J. Mairs, Natasha E. Fullerton, Emilio Cosimo, Marie Boyd,